新型血清肿瘤标志物RCAS1在胰腺疾病中的作用
Novel serum tumor marker, RCAS1, in pancreatic diseases.
作者信息
Yamaguchi Koji, Enjoji Munechika, Nakashima Manabu, Nakamuta Makoto, Watanabe Takashi, Tanaka Masao
机构信息
Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
出版信息
World J Gastroenterol. 2005 Sep 7;11(33):5199-202. doi: 10.3748/wjg.v11.i33.5199.
AIM
As tumor markers for pancreatic carcinoma, carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 have been used, but the sensitivity and specificity are not enough for the diagnosis of pancreatic carcinoma.
METHODS
A novel serum tumor marker, RCAS1, was compared with two conventional serum tumor markers, CEA (highly specific for pancreatic cancer) and CA 19-9 (highly sensitive for pancreatic cancer), in 48 patients with pancreatic exocrine tumors.
RESULTS
When the diagnosis of benign or malignant conditions was examined by one tumor marker, the sensitivity of RCAS1 alone (55%) was higher than that of CEA alone (27%) and the specificity of RCAS1 alone (92%) was greater than that of CA19-9 alone (78%). When examined by a combination of two markers, the sensitivity of a combination of RCAS1 and CA19-9 (95%) was superior to those of CA19-9 alone (78%), RCAS1 alone (55%, P = 0.002), CEA alone (27%) (P<0.001), RCAS1 and CEA (59%) and CA19-9 and CEA (82%).
CONCLUSION
These results suggest that the combination of RCAS1 and CA19-9 is highly sensitive for pancreatic carcinoma.
目的
癌胚抗原（CEA）和糖类抗原（CA）19-9已被用作胰腺癌的肿瘤标志物，但它们对胰腺癌诊断的敏感性和特异性不足。
方法
在48例胰腺外分泌肿瘤患者中，将一种新型血清肿瘤标志物RCAS1与两种传统血清肿瘤标志物CEA（对胰腺癌具有高度特异性）和CA 19-9（对胰腺癌具有高度敏感性）进行比较。
结果
当用一种肿瘤标志物检查良性或恶性疾病的诊断时，单独使用RCAS1的敏感性（55%）高于单独使用CEA的敏感性（27%），单独使用RCAS1的特异性（92%）大于单独使用CA19-9的特异性（78%）。当用两种标志物联合检查时，RCAS1和CA19-9联合使用的敏感性（95%）优于单独使用CA19-9（78%）、单独使用RCAS1（55%，P = 0.002）、单独使用CEA（27%）（P<0.001）、RCAS1和CEA联合使用（59%）以及CA19-9和CEA联合使用（82%）。
结论
这些结果表明，RCAS1和CA19-9联合使用对胰腺癌具有高度敏感性。
Zotero 插件